Arcus Ventures (AV) consists of a team of professionals with experience in clinical and academic medicine, drug development, hospital management, healthcare industry consulting and private equity. AV is dedicated to investing in oncology focused companies with innovative biopharmaceuticals and/or new drug delivery platforms in development.
Key people at Arcus Ventures.
Key people at Arcus Ventures.
Arcus Ventures is a New York–based venture capital and private equity firm specializing in early to late-stage investments in oncology-focused companies. Their mission centers on accelerating the development and commercialization of innovative cancer therapies, particularly in biopharmaceuticals, new drug delivery platforms, medical devices with pre-marketing approval, and service companies with positive revenue. The firm invests primarily in the United States, with a focus on sectors such as healthcare, biotechnology, pharmaceuticals, and health tech. By providing capital and strategic support, Arcus Ventures plays a significant role in advancing oncology research and improving patient outcomes, thereby impacting the startup ecosystem by nurturing high-potential companies in the cancer treatment space[1][2][4].
Founded in 2007, Arcus Ventures was established by a team of professionals with backgrounds in clinical and academic medicine, drug development, hospital management, healthcare consulting, and private equity. The firm’s founding vision was to leverage this multidisciplinary expertise to identify and support companies innovating in oncology. Over time, Arcus Ventures has evolved to maintain a strong focus on oncology while expanding its investment scope to include related biopharmaceuticals and medical devices. Key partners include Steven Soignet, Myoun, James Dougherty, Chad Hellmann, and Alex Zarbano, who bring extensive experience in healthcare and investment management[1][2][4][7].
Arcus Ventures rides the critical trend of precision oncology and biopharmaceutical innovation, a sector experiencing rapid scientific advances and increasing market demand due to rising cancer incidence globally. The timing is favorable as breakthroughs in drug delivery and diagnostics are transforming cancer treatment paradigms. Market forces such as regulatory support for innovative therapies, growing healthcare expenditures, and patient advocacy amplify the firm's impact. By funding early-stage companies with promising technologies, Arcus Ventures influences the broader ecosystem by accelerating the translation of research into clinical applications, fostering collaboration, and driving competitive innovation in oncology[1][2][4].
Looking ahead, Arcus Ventures is well-positioned to capitalize on emerging trends in personalized medicine, immuno-oncology, and advanced drug delivery systems. Their continued focus on early and late-stage oncology ventures suggests a strategy to support companies through critical development milestones toward commercialization. As cancer therapies become more targeted and complex, the firm’s expertise and network will likely enhance its influence in shaping the future of oncology innovation. The evolving regulatory landscape and increasing integration of digital health tools may also open new investment avenues. Overall, Arcus Ventures is expected to remain a pivotal player in oncology venture capital, driving impactful advancements that align with their mission to improve cancer patient outcomes[1][2][4].
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 1, 2021 | Prilenia | $43.0M Series B | — | Forbion |
| Oct 1, 2021 | Rectify Pharmaceuticals | $100.0M Series A | — | Advanced Technology Ventures, Agent Capital, Atlas Venture, Forbion, Longwood Fund, OrbiMed, Pfizer Venture Investments |
| Jun 1, 2020 | Prilenia | $63.0M Series A | — | Forbion |
| May 1, 2019 | Cala Health | $50.0M Series C | — | Arboretum Ventures, Beringea, AlleyCorp, Alumni Ventures, Ascension Ventures, Bradley Horowitz, Charlie Cheever, Fifth Wall, Healthy Ventures, Jonathan Bush, Kevin Love, Rob May |
| Jul 1, 2017 | Exosome Diagnostics | $30.0M Series C | — | Forbion |
| Jan 1, 2016 | Exosome Diagnostics | $16.0M Series B | — | Forbion |
| Sep 1, 2015 | Exosome Diagnostics | $18.0M Series B | — | Forbion |
| Mar 1, 2014 | Exosome Diagnostics | $27.0M Series B | — | Forbion |
| Oct 1, 2013 | MI Bioresearch | $4.0M Series B | — | Arboretum Ventures, Beringea |
| Mar 1, 2012 | MI Bioresearch | $10.0M Series A | — | Arboretum Ventures, Beringea |
| May 1, 2011 | MI Bioresearch | $7.0M Series A | — | Arboretum Ventures, Beringea |
